Epigenomics Licenses Septin9 Biomarker to Companion Dx Lab for Colorectal Cancer Test | GenomeWeb

NEW YORK (GenomeWeb News) – Epigenomics today announced Companion Dx Reference Labs has obtained the rights to establish and commercialize a colorectal cancer test using the methylated Septin9 biomarker.

Under the terms of the deal, Companion Dx will be able to use Epigenomics' biomarker to create a blood-based, laboratory developed test, while Epigenomics is entitled to double-digit royalties on sales of the test. Other terms of the agreement were not disclosed.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Wall Street Journal reports that National Institutes of Health Director Francis Collins' response to contamination concerns at the agency might have delayed care.

The final revision of the Common Rule doesn't include the proposed change requiring consent for leftover biospecimens.

The first Reproducibility Project: Cancer Biology papers show mixed results.

In Nature this week: mobile phone-based targeted DNA sequencing, and more.